| |
Fuzeon Sales Increased; Trimeris Reports Third Quarter 2007 FUZEON Sales Results
|
| |
| |
* Global sales in the third quarter grew 17 percent over 2006
* U.S/Canada sales in the third quarter declined 9 percent over 2006
* Ex U.S/Canada sales in the third quarter grew 47 percent over 2006
MORRISVILLE, N.C.--(BUSINESS WIRE)--Trimeris, Inc. (Nasdaq: TRMS) today announced worldwide net sales of FUZEON for the third quarter of 2007 were $73.9 million, an increase of 17 percent from $63.0 million in the third quarter of 2006. Net sales of FUZEON in the U.S. and Canada for the third quarter of 2007 were $30.6 million, a decrease of 9 percent from $33.5 million in the third quarter of 2006. Net sales of FUZEON outside the U.S. and Canada for the third quarter of 2007 were $43.3 million, an increase of 47 percent from $29.5 million in the third quarter of 2006. All sales of FUZEON are recorded by F. Hoffmann-La Roche Ltd. ("Roche"), Trimeris' collaborative partner.
Worldwide net sales of FUZEON for the first nine months of 2007 were $200.3 million, an increase of 14 percent from $175.7 million in the first nine months of 2006. Net sales of FUZEON in the U.S. and Canada for the first nine months of 2007 were $92.8 million, an increase of 1 percent from $92.0 million in the first nine months of 2006. Net sales of FUZEON outside the U.S. and Canada for the first nine months of 2007 were $107.5 million, an increase of 28 percent from $83.7 million in the first nine months of 2006.
The release of complete financial results for the third quarter of 2007 will take place in early November, 2007.
Net Fuzeon Sales
The table below presents net FUZEON sales by quarter beginning in the first quarter of 2005:
About Trimeris, Inc.
Trimeris, Inc. (Nasdaq: TRMS) is a biopharmaceutical company engaged in the development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. FUZEON, approved in the U.S., Canada and European Union, is the first in a new class of anti-HIV drugs called fusion inhibitors. For more information about Trimeris, please visit the Company's website at http://www.trimeris.com.
|
|
| |
| |
|
|
|
